山崎　理絵 （ヤマザキ　リエ）

Yamazaki, Rie

写真a

所属（所属キャンパス）

医学部 輸血・細胞療法センター（輸血・細胞療法部） （信濃町）

職名

教授（有期）
このページの先頭へ▲
 

著書 【 表示 ／ 非表示 】

  • 日常外来で遭遇する 感染症診療ガイド

    山崎　理絵，　森　毅彦，　岡本 真一郎, 永井書店, 2006年04月

    担当範囲: 341-351

このページの先頭へ▲

論文 【 表示 ／ 非表示 】

  • Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high-performance liquid chromatography–Photodiode array detection

    Yokoyama Y., Nozawa E., Morita M., Ishikawa E., Mori T., Sakurai M., Kikuchi T., Matsuki E., Yamazaki R., Kataoka K., Jibiki A., Kawazoe H., Suzuki S., Nakamura T.

    Journal of Clinical Laboratory Analysis （Journal of Clinical Laboratory Analysis）  36 （ 8 ）  2022年08月

    ISSN  08878013

    　概要を見る

    Background: Dasatinib, nilotinib, and bosutinib, second-generation tyrosine kinase inhibitors (TKIs), and ponatinib, a third-generation TKI, are approved pharmaceuticals used in the treatment of chronic myeloid leukemia (CML). Although liquid chromatography-tandem mass spectrometry assays for simultaneous quantification of the four TKIs in human serum have been reported in the literature, a high-performance liquid chromatography (HPLC) assay that simultaneously quantifies these compounds has not yet been developed. This study aims to establish and validate an efficient HPLC analytical method using a photodiode array (PDA) detector for the simultaneous quantification of the four TKIs. Methods: Calibration standards were prepared by serial dilution of serum samples containing the four TKIs, followed by solid-phase extraction. The four TKIs were eluted in order within 10 min using a binary HPLC gradient system. Results: The calibration ranges were 2–500 ng/ml for dasatinib, 100–5000 ng/ml for nilotinib, and 10–500 ng/ml for bosutinib and ponatinib. Intra-day and inter-day precision and accuracy values were found to be in accordance with the U.S. Food and Drug Administration guidelines. The recovery rates were 92.9%–96.0%, 80.7%–86.1%, 91.6%–99.0%, and 86.4%–92.6% for dasatinib, nilotinib, bosutinib, and ponatinib, respectively. Conclusion: To the best of our knowledge, this is the first report of an HPLC-PDA analytical method that allows efficient simultaneous quantification of the four TKIs in the serum of patients with CML. We believe that the method developed herein can improve the efficiency of therapeutic drug monitoring in patients with CML in clinical practice.

  • Comparison of cryoprotectants in hematopoietic cell infusion–related adverse events

    Ikeda K., Minakawa K., Yamahara K., Yamada-Fujiwara M., Okuyama Y., Fujiwara S.i., Yamazaki R., Kanamori H., Iseki T., Nagamura-Inoue T., Kameda K., Nagai K., Fujii N., Ashida T., Hirose A., Takahashi T., Ohto H., Ueda K., Tanosaki R.

    Transfusion （Transfusion）  62 （ 6 ） 1280 - 1288 2022年06月

    ISSN  00411132

    　概要を見る

    Background: The standard cryoprotectant for human cellular products is dimethyl sulfoxide (DMSO), which is associated with hematopoietic cell infusion-related adverse events (HCI-AEs) in hematopoietic stem cell transplantation including peripheral blood stem cell (PBSC) transplantation (PBSCT). DMSO is often used with hydroxyethyl starch (HES), which reduces DMSO concentration while maintaining the postthaw cell recovery. The cryoprotectant medium CP-1 (Kyokuto Pharmaceutical Industrial) is widely used in Japan. After mixture of a product with CP-1, DMSO and HES concentrations are 5% and 6%, respectively. However, the safety profile of CP-1 in association with HCI-AEs has not been investigated. Study Design and Methods: To compare CP-1 with other cryoprotectants, we conducted a subgroup analysis of PBSCT recipients in a prospective surveillance study for HCI-AEs. Moreover, we validated the toxicity of CP-1 in 90 rats following various dose administration. Results: The PBSC products cryopreserved with CP-1 (CP-1 group) and those with other cryoprotectants, mainly 10% DMSO (non-CP-1 group), were infused into 418 and 58 recipients, respectively. The rate of ≥grade 2 HCI-AEs was higher in the CP-1 group, but that of overall or ≥grade 3 HCI-AEs was not significantly different, compared to the non-CP-1 group. Similarly, after propensity score matching, ≥grade 2 HCI-AEs were more frequent in the CP-1 group, but the ≥grade 3 HCI-AE rate did not differ significantly between the groups. No significant toxicity was detected regardless of the CP-1 dose in the 90 rats. Conclusions: Infusion of a CP-1-containing PBSC product is feasible with the respect of HCI-AEs.

  • Novel Indicators of Transplant Outcomes for PhALL: Current Molecular-Relapse-Free Survival

    Nakasone H., Kako S., Tachibana T., Tanaka M., Onizuka M., Takahashi S., Yokota A., Fujiwara S.I., Sakura T., Sakaida E., Fujisawa S., Yamazaki R., Gotoh M., Hagihara M., Aotsuka N., Tsukada N., Hatta Y., Shimizu H., Usuki K., Watanabe R., Mori T., Yano S., Kanamori H., Kanda Y.

    Transplantation and Cellular Therapy （Transplantation and Cellular Therapy）  27 （ 9 ） 800.e1 - 800.e8 2021年09月

    ISSN  26666367

    　概要を見る

    Molecular relapse after allogeneic hematopoietic cell transplantation (allo-HCT) has been thought to predict clinical relapse in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia (PhALL). Tyrosine kinase inhibitor (TKI) administration after allo-HCT may dynamically change the status from molecular relapse to molecular remission, but these state changes cannot be accurately represented by conventional survival indicators such as relapse-free survival, where events are usually considered irreversible. We aimed to develop novel indicators of transplant outcomes for allo-HCT recipients with PhALL and to visualize current molecular-relapse-free survival (CMRFS) and current on-TKI status (CTKI), treating molecular relapse or TKI administration after allo-HCT as a reversible event. We retrospectively analyzed 286 patients with PhALL who received allo-HCT between 2000 and 2016 in order to develop the indicators. CMRFS was defined as the probability of molecular remission without clinical relapse or death at any time after allo-HCT. Similarly, CTKI was defined as the probability of TKI administration without clinical relapse or death at any time after allo-HCT. The 1- and 5-year CMRFS rates were 67% and 59%, respectively, whereas the 1- and 5-year conventional molecular relapse-free survival rates were 42% and 37%. The 1- and 5-year CTKI rates were 14% and 8%, respectively. In a post hoc analysis focusing on patients who had achieved a molecular complete remission within 6 weeks (n = 201), the 5-year CMRFS rate (71%) was similar to the 5-year conventional molecular relapse-free survival (molRFS) rate (70%) in the non-TKI group. On the other hand, the 5-year CMRFS rate in the TKI group was 61%, whereas the 5-year conventional molRFS rate was only 38%. CMRFS and CTKI might become useful indicators of transplant success in terms of survival, leukemia-free status, and treatment-free status at any time point. Future extension of these survival models to other clinical situations is warranted.

  • Clinical results of a massive blood transfusion protocol for postpartum hemorrhage in a university hospital in japan: A retrospective study

    Ochiai D., Abe Y., Yamazaki R., Uemura T., Toriumi A., Matsuhashi H., Tanaka Y., Ikenoue S., Kasuga Y., Tanosaki R., Tanaka M.

    Medicina (Lithuania) （Medicina (Lithuania)）  57 （ 9 ）  2021年09月

    ISSN  1010660X

    　概要を見る

    Background and objectives: Massive postpartum hemorrhage (PPH) is the most common cause of maternal death worldwide. A massive transfusion protocol (MTP) may be used to provide significant benefits in the management of PPH; however, only a limited number of hospitals use MTP protocol to manage massive obstetric hemorrhages, especially in Japan. This study aimed to assess the clinical outcomes in patients in whom MTP was activated in our hospital. Materials and Methods: We retrospectively reviewed the etiology of PPH, transfusion outcomes, and laboratory findings among the patients treated with MTP after delivery in our hospital. Results: MTP was applied in 24 cases (0.7% of deliveries). Among them, MTP was activated within 2 h of delivery in 15 patients (62.5%). The median estimated blood loss was 5017 mL. Additional procedures to control bleeding were performed in 19 cases, including transarterial embolization (18 cases, 75%) and hysterectomy (1 case, 4.2%). The mean number of units of red blood cells, fresh frozen plasma, and platelets were 17.9, 20.2, and 20.4 units, respectively. The correlation coefficients of any two items among red blood cells, fresh frozen plasma, platelets, blood loss, and obstetrical disseminated intravascular coagulation score ranged from 0.757 to 0.892, indicating high levels of correlation coefficients. Although prothrombin time and activated partial thromboplastin time levels were significantly higher in the <150 mg/dL fibrinogen group than in the ≥150 mg/dL fibrinogen group at the onset of PPH, the amount of blood loss and blood transfusion were comparable between the two groups. Conclusions: Our MTP provides early access to blood products for patients experiencing severe PPH and could contribute to improving maternal outcomes after resuscitation in our hospital. Our study suggests the implementation of a hospital-specific MTP protocol to improve the supply and utilization of blood products to physicians managing major obstetric hemorrhage.

  • Toxoplasmosis after allogeneic hematopoietic stem cell transplantation: Impact of serostatus-based management

    Amikura T., Kikuchi T., Kato J., Koda Y., Sakurai M., Yamazaki R., Mikita K., Saburi M., Nakazato T., Mori T.

    Transplant Infectious Disease （Transplant Infectious Disease）  23 （ 3 ）  2021年06月

    ISSN  13982273

    　概要を見る

    Toxoplasmosis caused by Toxoplasma gondii (T. gondii) is a serious infectious complication after allogeneic hematopoietic stem cell transplantation (HSCT). The incidence of toxoplasmosis varies widely because of the variabilities of seroprevalence among patient populations. The incidence and the optimal management of toxoplasmosis after allogeneic HSCT in a patient population with a low seroprevalence have not been fully evaluated. We conducted a single-center retrospective study evaluating toxoplasmosis in Japanese patients who underwent allogeneic HSCT. Of the 728 evaluable patients, only 5 developed toxoplasmosis with a median onset of day 60 post-transplant (range, day 55-393). The cumulative incidence was 0.7% (95% CI: 0.3%-1.5%) at day 500 post-transplant. Four of the five patients succumbed due to toxoplasmosis. The more recently treated 220 patients (not the earlier 508 patients) were screened for the T. gondii serostatus, and prophylactic treatment with trimethoprim/sulfamethoxazole was applied. All five patients with toxoplasmosis were in the unscreened group, and there was no case of toxoplasmosis after the introduction of the screening and prophylactic treatment. Our results suggest that toxoplasmosis after allogeneic HST is rare but can develop as a life-threatening complication even in the populations with low seroprevalence, and that prophylactic treatment for seropositive patients could effectively prevent toxoplasmosis.

全件表示 >>

このページの先頭へ▲

KOARA（リポジトリ）収録論文等 【 表示 ／ 非表示 】

このページの先頭へ▲

総説・解説等 【 表示 ／ 非表示 】

このページの先頭へ▲

研究発表 【 表示 ／ 非表示 】

  • Evaluation of the platelet-specific antibody response in thrombocytopenia following allogeneic hematopoietic stem cell transplantation.

    Yamazaki Rie, Mori Takehiko, Kuwana Masataka, Okazaki Y., Kawakami Yutaka, Ikeda Yasuo Okamoto Shinichiro

    ASBMT/IBMTR Tandem BMT Meetings （Orlando, Florida） , 

    2004年02月
    , 

    ポスター発表

  • Allogeneic stem cell transplantation using high-dose cytarabine combined with G-SCF and TBI as conditioning for chronic myelogenours leukemia (CML) in advanced stage

    Yamazaki Rie, Mori Takehiko, Shimizu Takayuki, Aisa Yoshinobu, Ikeda Yasuo, Okamoto Shinichiro

    ASBMT/IBMTR Tandem BMT Meetings, 

    2003年01月
    , 

    ポスター発表

  • Cytomegalovirus (CMV) gastrointestinal disease in allogeneic hematopoietic stem cell transplant recipients under preemptive therapy based on CMV antigenemia or polymerase chain reaction

    Mori Takehiko, Shimizu Takayuki, Aisa Yoshinobu, Nishida Hiroko, Yamazaki Rie, Ikeda Yasuo, Okamoto Shinichiro

    ASBMT/IBMTR Tandem BMT Meetings, 

    2003年01月
    , 

    ポスター発表

  • Allogeneic stem cell transplantation using high-dose cytarabine combined with G-SCF and TBI as conditioning for chronic myelogenours leukemia (CML) in advanced stage

    Yamazaki Rie, Mori Takehiko, Shimizu Takayuki, Aisa Yoshinobu, Ikeda Yasuo, Okamoto Shinichiro

    ASBMT/IBMTR Tandem BMT Meetings, 

    2003年01月
    , 

    ポスター発表

  • 同種造血幹細胞移植において検出される同種抗原特異的T細胞と認識抗原の同定－選択的GVLに向けて－

    山崎理絵，河上裕

    第2回臨床免疫研究会, 

    2002年06月
    , 

    口頭発表（一般）

全件表示 >>

このページの先頭へ▲

競争的研究費の研究課題 【 表示 ／ 非表示 】

  • 同種造血細胞移植後ヒトヘルペスウイルス6型再活性化の免疫機構の解明と予防法の確立

    2017年04月
    -
    2020年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 山崎　理絵, 基盤研究(C), 補助金,  研究代表者

このページの先頭へ▲
 

担当授業科目 【 表示 ／ 非表示 】

  • 輸血臨床実習

    2025年度

  • 内科学（血液）講義

    2025年度

  • 内科学演習

    2025年度

  • 内科学実習

    2025年度

  • 内科学特論

    2025年度

全件表示 >>

このページの先頭へ▲